Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?

Eur Urol. 2008 Sep;54(3):489-92. doi: 10.1016/j.eururo.2007.12.041. Epub 2008 Jan 11.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / surgery*
  • Carcinoma, Renal Cell / therapy
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Humans
  • Indoles / therapeutic use
  • Interferon-alpha / therapeutic use
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery*
  • Kidney Neoplasms / therapy
  • Nephrectomy / methods*
  • Protein Kinases / therapeutic use
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Sunitinib
  • Survival Analysis
  • TOR Serine-Threonine Kinases
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Indoles
  • Interferon-alpha
  • Pyrazoles
  • Pyrimidines
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sunitinib